Drug intelligence / Profile preview

CGEN-25009

Development stage: Preclinical
Lead developer: Compugen
Modality: Peptides

Overview

**CGEN-25009** is a novel synthetic peptide agonist of the relaxin receptor (also known as LGR7 or RXFP1), discovered by Compugen using their GPCR Peptide Ligand Discovery Platform. It activates the relaxin family peptide receptor 1, exhibiting antifibrotic and anti-inflammatory properties in preclinical models, particularly preventing bleomycin-induced pulmonary fibrosis in animal studies. Developed by Compugen for potential treatment of inflammatory, cardiovascular, and respiratory diseases, with a focus on pulmonary fibrosis.[1][3][7][11]

Targets

RXFP1 (Relaxin family peptide receptor 1)RXFP2 (Relaxin family peptide receptor 2)

Beyond the preview

Go deeper on CGEN-25009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGEN-25009.

Explore the full profile